Detalhe da pesquisa
1.
Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients.
Ann Surg Oncol
; 30(8): 5239-5247, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37154970
2.
A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores.
Breast Cancer Res Treat
; 189(2): 455-461, 2021 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-34131830
3.
Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients.
BMC Cancer
; 21(1): 1332, 2021 Dec 14.
Artigo
Inglês
| MEDLINE | ID: mdl-34906120
4.
A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier.
Oncology
; 98(8): 534-541, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32235113
5.
ASO Visual Abstract: Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients.
Ann Surg Oncol
; 30(8): 5250-5251, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37266811
6.
Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer.
BMC Cancer
; 14: 755, 2014 Oct 09.
Artigo
Inglês
| MEDLINE | ID: mdl-25301183
7.
Species differences between human and rat in the substrate specificity of cathepsin K.
J Biochem
; 144(4): 499-506, 2008 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-18664521
8.
New chemotypes for cathepsin K inhibitors.
Bioorg Med Chem Lett
; 18(8): 2599-603, 2008 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-18375120
9.
A new cancer diagnostic system based on a CDK profiling technology.
Biochim Biophys Acta
; 1741(3): 226-33, 2005 Sep 25.
Artigo
Inglês
| MEDLINE | ID: mdl-15990281
10.
Novel scaffold for cathepsin K inhibitors.
Bioorg Med Chem Lett
; 17(22): 6096-100, 2007 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-17911019